钠-葡萄糖协同转运蛋白2抑制剂在室性心律失常中的研究进展

Research Progress on Sodium-glucose Cotransporter 2 Inhibitors in Ventricular Arrhythmias

钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)是一种新型降糖药,通过阻断肾脏近端小管对葡萄糖的重吸收而降低血糖。SGLT2i可以通过减弱动作电位持续时间(APD)/QT间期的延长、改善心脏离子电流稳态、抑制交感神经系统活性、减轻体重及脱靶效应等机制减少室性心律失常的发生。因此,对SGLT2i在室性心律失常中的研究进展及可能的作用机制进行综述。

Sodium-glucose cotransporter 2 inhibitors is a novel hypoglycemic drug that lowers blood sugar by blocking the reabsorption of glucose by the proximal tubules of the kidney.SGLT2i can reduce the occurrence of ventricular arrhythmias by reducing the prolongation of Action potential duration/QT interval,improving cardiac ionic current homeostasis,inhibiting the activity of sympathetic nervous system,and reducing body weight and the miss target effect.Therefore,the study reviews the research progress and possible mechanisms of SGLT2i in ventricular arrhythmias.